Neoral induction in pediatric renal transplantation

Area of Science:

• Nephrology
• Pharmacology
• Pediatric Transplantation

Background:

• Cyclosporine is a key immunosuppressant in renal transplantation.
• Neoral, a newer formulation, was hypothesized to offer more predictable cyclosporine pharmacokinetics than Sandimmun.
• Pediatric patients may metabolize cyclosporine differently, potentially impacting drug levels.

Purpose of the Study:

• To compare the trough cyclosporine levels and clinical outcomes in pediatric renal transplant patients receiving Neoral versus Sandimmun.
• To evaluate the impact of Neoral's rapid absorption and peak on dosing requirements and toxicity in children.

Main Methods:

• A comparative study involving nine pediatric renal transplant patients on Neoral and nine on Sandimmun.
• Monitoring of trough cyclosporine levels at specified intervals post-transplantation.
• Assessment of clinical parameters including creatinine levels, blood pressure, and medication use.

Main Results:

• Neoral required more frequent (every 8-hour) dosing during the initial month to achieve comparable trough levels to Sandimmun.
• After 4-6 weeks, trough levels were similar between the two formulations.
• Neoral group showed similar 1-month creatinine and blood pressure but required significantly more antihypertensive medications.

Conclusions:

• Neoral's pharmacokinetic profile in pediatric renal transplant recipients necessitates adjusted initial dosing frequencies.
• While trough levels normalize over time, increased blood pressure medication use in the Neoral group warrants attention.
• Further investigation into the area under the curve differences between Neoral and Sandimmun is suggested.